

Paul J Thornalley

Research Director, Diabetes Research Center, QBRI

Dr Paul gained a BSc in Chemistry, University of Manchester, UK, in 1979 and a PhD in Biochemistry, University of Oxford, UK, in 1982. He spent one year as a postdoctoral researcher in New York University Medical School, Department of Pharmacology, before in 1983 becoming Lecturer in Toxicology at Aston University, Birmingham, UK. In 1988, he moved to the University of Essex, Colchester, UK, as lecturer and then became Senior Lecturer, Reader and Professor in Disease Mechanisms and Therapeutics. In 2007, he became Professor of Systems Biology, Warwick Medical School, University of Warwick, UK, and in October 2018, relocated to Qatar to join QBRI as Research Director, Diabetes Research Center. He has 529 publications and 14 patents, receiving ca. 33,000 citations, h-index 96. Dr Paul is a leading international diabetes researcher, influencing many in his field – particularly studies of the involvement of reactive metabolite “methylglyoxal” in the development of chronic vascular complications of diabetes in which he is considered founding investigator.

Research at QBRI:

Dr Paul is pursuing research with colleagues to identify mechanisms of development of type 2 diabetes and diabetic vascular complications, biomarkers for detection and risk of progression of prediabetes and diabetic vascular complications, and approaches to precision medicine. He collaborates with colleagues in CHLS, Qatar University, Weill Cornell College of Medicine-Qatar, Qatar Biobank and Hamad Medical Corporation in Qatar and multiple leading research teams internationally.